IR@PKUHSC  > 北京大学第三临床医学院  > 眼科
学科主题临床医学
Intraocular pressure lowering efficacy and safety of travoprost 0.004% as a replacement therapy in patients with open angle glaucoma or ocular hypertension
Ge Jian1; Sun Xing-huai2; Wang Ning-li3; Zhao Jia-liang4; Wu Ling-ling5; Chen Xiao-ming6; Wang Zhi-xin7; Li, Benny7
关键词travoprost prostaglandin analogue intraocular pressure glaucoma
刊名CHINESE MEDICAL JOURNAL
2010-06-05
DOI10.3760/cma.j.issn.0366-6999.2010.11.012
123期:11页:1417-1421
收录类别SCI
文章类型Article
WOS标题词Science & Technology
类目[WOS]Medicine, General & Internal
研究领域[WOS]General & Internal Medicine
关键词[WOS]FP PROSTAGLANDIN RECEPTOR ; CALCIUM MOBILIZATION ; TIMOLOL 0.5-PERCENT ; MULTICENTER TRIAL ; CLINICAL-TRIAL ; LATANOPROST ; BIMATOPROST ; 6-MONTH ; MEDICATION
英文摘要

Background Travoprost has been widely used for the treatment of patients with open-angle glaucoma (OAG) or ocular hypertension (OH). The aim of this study was to evaluate the intraocular pressure (IOP) lowering efficacy of travoprost 0.004% monotherapy in patients previously treated with other topical hypotensive medications, and in previously untreated patients.

Methods This open-label, 12-week study in 1651 adult patients with ocular hypertension or open-angle glaucoma who were untreated or required a change in therapy (due to either inadequate efficacy or safety issues) as judged by the investigator was conducted at 6 sites in China. Previously treated patients were instructed to discontinue their prior medications at the first visit. All the patients were dosed with travoprost 0.004% once-daily at 8 p.m. in both eyes for 12 weeks. Efficacy and safety evaluations were conducted at week 4 and 12. IOP measurements were performed at the same time of day at the follow-up visits.

Results For patients transitioned to travoprost, mean IOP reductions from baseline in untreated and treated patients with different prior medications at week 12 were: latanoprost, (4.3+/-4.6) mmHg; beta-blocker, (6.3+/-4.0) mmHg; a-agonist, (7.5+/-4.3) mmHg; topical carbonic anhydrase inhibitors, (8.0+/-4.9) mmHg. All mean IOP changes from baseline were statistically significant (P <0.001). No treatment-related serious adverse events were reported in this study.

Conclusions In patients treated with other hypotensive medications or untreated, the IOP reduction with travoprost was significant. The results of this study demonstrated the potential benefit of using travoprost as a replacement therapy in order to ensure adequate IOP control. Travoprost administered once daily was safe and well tolerated in patients with glaucoma or ocular hypertension. Chin Med J 2010;123(11):1417-1421

语种英语
WOS记录号WOS:000278725700012
资助机构Alcon Research Ltd., Fort Worth, TX
引用统计
被引频次:1[WOS]   [WOS记录]     [WOS相关记录]
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/65354
专题北京大学第三临床医学院_眼科
作者单位1.Peking Univ, Hosp 3, Ctr Eye, Beijing 100191, Peoples R China
2.Sun Yat Sen Univ, Zhongshan Ophthalm Ctr, State Key Lab Ophthalmol, Guangzhou 510060, Guangdong, Peoples R China
3.Fudan Univ, Sch Med, Dept Ophthalmol, Eye Ear Nose & Throat Hosp, Shanghai 200031, Peoples R China
4.Capital Med Univ, Beijing Tongren Eye Ctr, Beijing Tongren Hosp, Beijing Ophthalmol & Visual Sci Key Lab, Beijing 100730, Peoples R China
5.Alcon Res Ltd, Ft Worth, TX 76134 USA
6.Chinese Acad Med Sci, Peking Union Med Coll Hosp, Dept Ophthalmol, Beijing 100730, Peoples R China
7.Sichuan Univ, W China Hosp, Dept Ophthalmol, Chengdu 610041, Sichuan, Peoples R China
推荐引用方式
GB/T 7714
Ge Jian,Sun Xing-huai,Wang Ning-li,et al. Intraocular pressure lowering efficacy and safety of travoprost 0.004% as a replacement therapy in patients with open angle glaucoma or ocular hypertension[J]. CHINESE MEDICAL JOURNAL,2010,123(11):1417-1421.
APA Ge Jian.,Sun Xing-huai.,Wang Ning-li.,Zhao Jia-liang.,Wu Ling-ling.,...&Li, Benny.(2010).Intraocular pressure lowering efficacy and safety of travoprost 0.004% as a replacement therapy in patients with open angle glaucoma or ocular hypertension.CHINESE MEDICAL JOURNAL,123(11),1417-1421.
MLA Ge Jian,et al."Intraocular pressure lowering efficacy and safety of travoprost 0.004% as a replacement therapy in patients with open angle glaucoma or ocular hypertension".CHINESE MEDICAL JOURNAL 123.11(2010):1417-1421.
条目包含的文件
条目无相关文件。
个性服务
推荐该条目
保存到收藏夹
查看访问统计
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[Ge Jian]的文章
[Sun Xing-huai]的文章
[Wang Ning-li]的文章
百度学术
百度学术中相似的文章
[Ge Jian]的文章
[Sun Xing-huai]的文章
[Wang Ning-li]的文章
必应学术
必应学术中相似的文章
[Ge Jian]的文章
[Sun Xing-huai]的文章
[Wang Ning-li]的文章
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。